MS becomes a treatable disease: 30 years later

Area of Science:

• Neurology
• Immunology
• Genetics

Background:

• The first disease-modifying therapy for relapsing multiple sclerosis (MS) was approved 30 years ago.
• Significant advancements in MS therapeutics, immunopathogenesis, and genetics have enhanced disease understanding.
• Despite progress, a gap persists between treating relapsing MS and addressing progressive MS.

Purpose of the Study:

• To review lessons learned from the initial era of MS therapeutic development.
• To outline future directions for MS research and therapeutics.
• To address the unmet need in treating progressive multiple sclerosis.

Main Methods:

• This is a Personal Viewpoint article, not a primary research study.
• It synthesizes existing knowledge and expert opinion on MS treatment history and future prospects.
• Analysis of therapeutic development, immunopathogenesis, and genetic studies in multiple sclerosis.

Main Results:

• The first 30 years of MS therapy have seen major successes in managing relapsing forms of the disease.
• Progressive multiple sclerosis remains a critical area with limited effective treatments.
• Fundamental aspects of MS continue to be debated within the scientific community.

Conclusions:

• Lessons from the initial therapeutic era provide a foundation for future MS research.
• Addressing progressive MS and pursuing neuro-regeneration are key future challenges.
• The ultimate goal of a cure for multiple sclerosis remains a long-term aspiration.